OncoMatch/Clinical Trials/NCT04973306

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

Is NCT04973306 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Tislelizumab for esophageal squamous cell carcinoma stage ii.

Phase 2/3RecruitingShanghai Zhongshan HospitalNCT04973306Data as of May 2026

Treatment: Tislelizumab — The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy for locally advanced resectable esophageal squamous cell carcinoma (cII-III Stage) patient.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage II, III

Excluded: Stage CM+, CN3, CT4B, CTIS-1A, CT1BN0

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiotherapy

Cannot have received: targeted therapy

Cannot have received: immunotherapy

Lab requirements

Blood counts

white blood cells >4x10^9 /l; neutrophil >2.0×10^9 /l; hemoglobin > 90 g/l; platelets>100x10^9 /l

Kidney function

glomerular filtration rate (ccr) >60 ml/min; serum creatinine (scr) ≤120 µmol/l

Liver function

total bilirubin <1.5x uln; ast and alt <1.5x uln

Cardiac function

all patients should perform ecg, and those with a cardiac history or ecg abnormality should perform echocardiography with the left ventricular ejection fraction > 50 %

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify